Ranbaxy recalls nearly 30,000 packs of allergy-relief drug in U.S
MUMBAI (Reuters) - Drugmaker Ranbaxy Laboratories Ltd (RANB.NS) started recalling 29,790 packs of an allergy-relief medicine in the United States in February, after finding defects in the packaging, the U.S. Food and Drug Administration said.
The loratadine and pseudoephedrine sulphate extended release tablets being recalled carry an expiry date of September 2015, and were manufactured by Ranbaxy's Ohm Labs plant in New Jersey, which is the company's only facility making generics for the United States.
All other Ranbaxy plants, based in India, have been banned from exporting generics to the United States after the FDA found manufacturing quality glitches that the agency believed could compromise the quality of medicines.
Rival Indian drugmaker Sun Pharmaceutical Industries Ltd (SUN.NS) agreed to buy Ranbaxy last month in a $3.2 billion deal, betting it can fix Ranbaxy's problems.
The FDA classified the recall by Ohm Labs as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences.
Ranbaxy did not immediately respond to requests for comment.
(Reporting by Zeba Siddiqui in MUMBAI; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- REFILE-British Muslims urge cooperation in Foley murder hunt
- UPDATE 4-Family Dollar spurns Dollar General bid on antitrust concerns
- UPDATE 5-U.S. aid workers who survived Ebola leave Atlanta hospital
- Ukraine's Poroshenko talks tough ahead of meetings with Merkel, Putin
Government officials painted an upbeat picture for the economy on Thursday as it struggles to emerge from the longest spell of sub-par growth in decades and promised to tighten up risk management at the country's dominant state banks. Full Article